American Association for Cancer Research (AACR) Annual Meeting 2020
This conference has been POSTPONED.
The revised dates will be updated soon after they are confirmed.
American Association for Cancer Research (AACR) Annual Meeting 2020 is organized by the American Association for Cancer Research (AACR). The session will be held from Apr 24 - 29, 2020 at San Diego Convention Center, San Diego, California, United States of America.
Credit Designation Statement:
AACR has assigned this live session for a maximum of 47.0 AMA PRA Category 1 Credit(s)™. Physicians can claim credit commensurate with the extent of their participation in the activity.
ABIM MOC Statement:
Successful completion of this CME activity allows the participant to earn up to 47.0 MOC points in the American Board of Internal Medicine. It is the CME activity provider's responsibility to present a participant complete information to the ACCME for the purpose of granting MOC credit.
Statement of Educational Need, Target Audience, and Learning Objectives:
The fight against cancer is rapidly progressing with the accelerating pace of discoveries in the basic, translational, and clinical sciences. This is due in large part to the advent of new technologies, such as advanced live imaging techniques and liquid biopsies, and our increased understanding of the importance of harnessing the power of the immune system to develop new immunotherapies. However, understanding and combating the processes of cancer initiation, progression, and response to treatment require a multidisciplinary approach. The AACR Annual Meeting brings together cancer biologists, clinical oncologists, and population scientists with engineers, computational biologists, and physical scientists to develop quantitative approaches and ask new questions to develop better strategies for curing cancer. By bridging the gap between what physicians understand about cancer biology and the clinical applications, this meeting aids basic researchers, physicians, and clinician-scientists in obtaining, synthesizing, and integrating the most current molecular-based tests to aid in the diagnosis, treatment, and prevention of cancer. Further, facilitating the interface between physicians and scientists increases the contributions of laboratory research to drug development as well as patient care, transforms the design and conduct of clinical research protocols, and creates an avenue for the rapid translation of laboratory research findings from "bench-to-bedside" for the benefit of improving patient outcomes. This meeting also acts as a forum to discuss cancer health disparities and help ensure that all patients benefit from emerging breakthroughs in research and cancer treatment.
Despite the enormous progress in the field, cancer continues to be a global public health challenge, accounting for one in every six deaths that occur around the world. In the United States (U.S.) alone, it is predicted that 609,640 people will die from some form of cancer in 2018, making it the second most common cause of death after heart disease. One of the challenges we face is that cancer comprises more than 200 different diseases. For many of the most commonly diagnosed cancers in the U.S.—including lung, prostate, ovarian, urinary bladder, and colorectal cancer—incidence has been declining for more than a decade. However, the incidence of other forms of cancer—including endometrial, liver, thyroid, skin, childhood cancer, and leukemia—has been on the rise. Incidence, diagnosis, access to treatment, and survival rates are also impacted by the cancer health disparities that exist in certain segments of the U.S. population, with older and underprivileged populations often witnessing higher incidences of cancer and mortality.
This conference will bring together over 23,000 investigators from the basic, translational, and clinical disciplines and provide them with a venue to discuss their recent advances, test new hypotheses, and establish new collaborations. To provide the most advanced technologies and treatments, it is critical to bridge the gap between physicians who are answering fundamental questions about cancer biology and clinicians who are applying the latest diagnostic and treatment advances to patient care. As the incidence of cancer continues to increase, the fields of cancer prevention and early interception offer unprecedented opportunities to decrease the worldwide burden of cancer.
After participating in this CME activity, physicians should be able to:
• Assess the technological advances and tools, such as liquid biopsies, being used to accelerate progress in cancer research and improve early detection and an early interception, with the ultimate goal of extending patients' lives and improving their quality of life.
• Articulate how advances in precision cancer medicine are leading to improved patient outcomes.
• Incorporate the latest research findings regarding therapies and treatment options, including immunotherapy and combination therapies, in a variety of cancer types to improve patient outcomes.
• Formulate new strategies integrating multidisciplinary scientific and clinical research efforts towards the prevention, early detection, and interception of cancer.
• Identify factors that impact the diagnosis, treatment, and prevention of various forms of cancers in patients from diverse populations.
• Develop collaborations among physicians, researchers, and clinician-scientists to advance approaches for cancer treatment and prevention.
Additional details will be posted as soon as they are available.
- CME : 47
- MOC : 47
Toll free Number
Browse CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Infectious Disease
- Medical Education
- Immunology and Microbiology
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine